Cargando…

A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab

Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare neoplasm with poor prognosis and no established treatment. A 50-year-old man presented with fever, was found to have a mass measuring 14 cm in the right upper lobe of the chest, along with right pleural effusion on computed tomography (CT)....

Descripción completa

Detalles Bibliográficos
Autores principales: Sawatari, Kosuke, Izumi, Motohiro, Sone, Risa, Hattori, Tsuyoshi, Sugimoto, Akira, Eguchi, Yosuke, Mamoto, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760426/
https://www.ncbi.nlm.nih.gov/pubmed/35059287
http://dx.doi.org/10.1016/j.rmcr.2022.101579
_version_ 1784633317397626880
author Sawatari, Kosuke
Izumi, Motohiro
Sone, Risa
Hattori, Tsuyoshi
Sugimoto, Akira
Eguchi, Yosuke
Mamoto, Takashi
author_facet Sawatari, Kosuke
Izumi, Motohiro
Sone, Risa
Hattori, Tsuyoshi
Sugimoto, Akira
Eguchi, Yosuke
Mamoto, Takashi
author_sort Sawatari, Kosuke
collection PubMed
description Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare neoplasm with poor prognosis and no established treatment. A 50-year-old man presented with fever, was found to have a mass measuring 14 cm in the right upper lobe of the chest, along with right pleural effusion on computed tomography (CT). Positron emission tomography-CT revealed abnormal tracer uptake in the area corresponding to the mass in the upper lobe. Hence, convex-probe endobronchial ultrasound-guided transbronchial needle aspiration was performed. Histological examination revealed dense proliferation of spindle tumor cells and no programmed death-ligand 1 (PD-L1) expression. Thus, he was diagnosed with PSC (cT4N0M1a, clinical stage IVA), and four-agent combination chemotherapy with atezolizumab, carboplatin, paclitaxel, and bevacizumab was initiated. Marked shrinkage of the mass and symptomatic improvements were observed following the treatment initiation. Tumor shrinkage was further noted after shifting to maintenance therapy with atezolizumab and bevacizumab; the patient exhibited no symptom exacerbation 2 years later and continued the treatment. Our case showed that four-agent combination chemotherapy with atezolizumab, carboplatin, paclitaxel, and bevacizumab could be an effective treatment option for advanced PSC with or without PD-L1 expression.
format Online
Article
Text
id pubmed-8760426
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87604262022-01-19 A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab Sawatari, Kosuke Izumi, Motohiro Sone, Risa Hattori, Tsuyoshi Sugimoto, Akira Eguchi, Yosuke Mamoto, Takashi Respir Med Case Rep Case Report Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare neoplasm with poor prognosis and no established treatment. A 50-year-old man presented with fever, was found to have a mass measuring 14 cm in the right upper lobe of the chest, along with right pleural effusion on computed tomography (CT). Positron emission tomography-CT revealed abnormal tracer uptake in the area corresponding to the mass in the upper lobe. Hence, convex-probe endobronchial ultrasound-guided transbronchial needle aspiration was performed. Histological examination revealed dense proliferation of spindle tumor cells and no programmed death-ligand 1 (PD-L1) expression. Thus, he was diagnosed with PSC (cT4N0M1a, clinical stage IVA), and four-agent combination chemotherapy with atezolizumab, carboplatin, paclitaxel, and bevacizumab was initiated. Marked shrinkage of the mass and symptomatic improvements were observed following the treatment initiation. Tumor shrinkage was further noted after shifting to maintenance therapy with atezolizumab and bevacizumab; the patient exhibited no symptom exacerbation 2 years later and continued the treatment. Our case showed that four-agent combination chemotherapy with atezolizumab, carboplatin, paclitaxel, and bevacizumab could be an effective treatment option for advanced PSC with or without PD-L1 expression. Elsevier 2022-01-04 /pmc/articles/PMC8760426/ /pubmed/35059287 http://dx.doi.org/10.1016/j.rmcr.2022.101579 Text en © 2022 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Sawatari, Kosuke
Izumi, Motohiro
Sone, Risa
Hattori, Tsuyoshi
Sugimoto, Akira
Eguchi, Yosuke
Mamoto, Takashi
A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab
title A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab
title_full A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab
title_fullStr A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab
title_full_unstemmed A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab
title_short A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab
title_sort case of pd-l1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760426/
https://www.ncbi.nlm.nih.gov/pubmed/35059287
http://dx.doi.org/10.1016/j.rmcr.2022.101579
work_keys_str_mv AT sawatarikosuke acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT izumimotohiro acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT sonerisa acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT hattoritsuyoshi acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT sugimotoakira acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT eguchiyosuke acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT mamototakashi acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT sawatarikosuke caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT izumimotohiro caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT sonerisa caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT hattoritsuyoshi caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT sugimotoakira caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT eguchiyosuke caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab
AT mamototakashi caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab